Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Feb 13 2012 Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes Feb 06 2012 Cyclacel to Present at Upcoming Investor Conferences Jan 11 2012 Cyclacel Provides Corporate Update at OneMedForum Conference Jan 06 2012 Cyclacel to Present at the 5th Annual OneMedForum in San Francisco Dec 12 2011 Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML Dec 07 2011 Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients Dec 01 2011 Cyclacel to Webcast Analyst & Institutional Investor Meeting Wednesday, December 7, 2011 Nov 14 2011 Cyclacel Pharmaceuticals Reports Third Quarter 2011 Financial Results Nov 07 2011 Cyclacel to Announce Third Quarter 2011 Financial Results and Upcoming Corporate Events Oct 19 2011 Cyclacel to Present at BIO Investor Forum Oct 13 2011 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine Sep 22 2011 Cyclacel Receives Deficiency Notice from NASDAQ Global Select Market Aug 30 2011 Cyclacel announces commencement of investigator-initiated phase 2 trial of sapacitabine in patients with CLL or SLL hematological malignancies and 11q22-23 deletion Aug 11 2011 Cyclacel reports second quarter 2011 financial results Aug 09 2011 Cyclacel Pharmaceuticals to announce release of second quarter 2011 financial results Jul 18 2011 Cyclacel Pharmaceuticals amends its sapacitabine license agreement with Daiichi-Sankyo Jul 07 2011 Cyclacel announces closing of underwritten offering of common stock and warrants Jul 01 2011 Cyclacel Pharmaceuticals, Inc. announces pricing of underwritten offering of common stock and warrants Jun 06 2011 Interim results from Cyclacel clinical study highlight safety and efficacy of sequential administration of sapacitabine and decitabine in elderly patients with AML May 19 2011 Cyclacel to report new sapacitabine clinical data at the American Society of Clinical Oncology Annual Meeting May 12 2011 Cyclacel Pharmaceuticals reports financial results for first quarter 2011 May 09 2011 Cyclacel to announce release of first quarter 2011 financial results Apr 04 2011 Cyclacel announces presentation of preclinical data demonstrating combination potential of clinical agents at AACR Annual Meeting Apr 04 2011 Cyclacel to participate in a lymphoma and leukemia panel at Leerink Swann cancer roundtable conference Mar 31 2011 Cyclacel Pharmaceuticals to restate 2009 Annual and 2010 Quarterly Financial Statements to correct Consolidated Balance Sheets and Consolidated Statement of Stockholders’ Equity; No impact on results of operations. Pagination First page « first Previous page ‹ previous … Page 9 Page 10 Page 11 Page 12 Current page 13 Page 14 Page 15 Page 16 Page 17 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Feb 13 2012 Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes Feb 06 2012 Cyclacel to Present at Upcoming Investor Conferences Jan 11 2012 Cyclacel Provides Corporate Update at OneMedForum Conference Jan 06 2012 Cyclacel to Present at the 5th Annual OneMedForum in San Francisco Dec 12 2011 Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML Dec 07 2011 Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients Dec 01 2011 Cyclacel to Webcast Analyst & Institutional Investor Meeting Wednesday, December 7, 2011 Nov 14 2011 Cyclacel Pharmaceuticals Reports Third Quarter 2011 Financial Results Nov 07 2011 Cyclacel to Announce Third Quarter 2011 Financial Results and Upcoming Corporate Events Oct 19 2011 Cyclacel to Present at BIO Investor Forum Oct 13 2011 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine Sep 22 2011 Cyclacel Receives Deficiency Notice from NASDAQ Global Select Market Aug 30 2011 Cyclacel announces commencement of investigator-initiated phase 2 trial of sapacitabine in patients with CLL or SLL hematological malignancies and 11q22-23 deletion Aug 11 2011 Cyclacel reports second quarter 2011 financial results Aug 09 2011 Cyclacel Pharmaceuticals to announce release of second quarter 2011 financial results Jul 18 2011 Cyclacel Pharmaceuticals amends its sapacitabine license agreement with Daiichi-Sankyo Jul 07 2011 Cyclacel announces closing of underwritten offering of common stock and warrants Jul 01 2011 Cyclacel Pharmaceuticals, Inc. announces pricing of underwritten offering of common stock and warrants Jun 06 2011 Interim results from Cyclacel clinical study highlight safety and efficacy of sequential administration of sapacitabine and decitabine in elderly patients with AML May 19 2011 Cyclacel to report new sapacitabine clinical data at the American Society of Clinical Oncology Annual Meeting May 12 2011 Cyclacel Pharmaceuticals reports financial results for first quarter 2011 May 09 2011 Cyclacel to announce release of first quarter 2011 financial results Apr 04 2011 Cyclacel announces presentation of preclinical data demonstrating combination potential of clinical agents at AACR Annual Meeting Apr 04 2011 Cyclacel to participate in a lymphoma and leukemia panel at Leerink Swann cancer roundtable conference Mar 31 2011 Cyclacel Pharmaceuticals to restate 2009 Annual and 2010 Quarterly Financial Statements to correct Consolidated Balance Sheets and Consolidated Statement of Stockholders’ Equity; No impact on results of operations. Pagination First page « first Previous page ‹ previous … Page 9 Page 10 Page 11 Page 12 Current page 13 Page 14 Page 15 Page 16 Page 17 … Next page next › Last page last »
Feb 13 2012 Cyclacel Provides Update on Clinical Progress With Sapacitabine as Second Line Therapy in Older Patients With Myelodysplastic Syndromes
Dec 12 2011 Updated Results From Cyclacel Clinical Study Highlight Safety and Efficacy of Sequential Administration of Sapacitabine and Decitabine in Elderly Patients With AML
Dec 07 2011 Cyclacel Provides Update on Clinical Progress With Sapacitabine in Solid Tumors Including Activity in BRCA Mutation-Positive Patients
Oct 13 2011 Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3 Trial of Sapacitabine
Aug 30 2011 Cyclacel announces commencement of investigator-initiated phase 2 trial of sapacitabine in patients with CLL or SLL hematological malignancies and 11q22-23 deletion
Jul 01 2011 Cyclacel Pharmaceuticals, Inc. announces pricing of underwritten offering of common stock and warrants
Jun 06 2011 Interim results from Cyclacel clinical study highlight safety and efficacy of sequential administration of sapacitabine and decitabine in elderly patients with AML
May 19 2011 Cyclacel to report new sapacitabine clinical data at the American Society of Clinical Oncology Annual Meeting
Apr 04 2011 Cyclacel announces presentation of preclinical data demonstrating combination potential of clinical agents at AACR Annual Meeting
Apr 04 2011 Cyclacel to participate in a lymphoma and leukemia panel at Leerink Swann cancer roundtable conference
Mar 31 2011 Cyclacel Pharmaceuticals to restate 2009 Annual and 2010 Quarterly Financial Statements to correct Consolidated Balance Sheets and Consolidated Statement of Stockholders’ Equity; No impact on results of operations.
